- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06776003
Continuous Mobility and Physical Activity in Vertebroplasty vs Sham for Osteoporotic Vertebral Fracture (VOPE2 COMPAS)
Continuous Mobility and Physical Activity in Vertebroplasty vs Sham for Osteoporotic Vertebral Fracture: a Single-center, Double-blind Randomized Controlled Clinical Trial
The aim of this clinical trial is to determine if vertebroplasty is an effective treatment for acute, painful vertebral fractures due to osteoporosis.
The focus of the study is on the physical activity and mobility of participants.
The main questions the trial aims to answer are:
- Does vertebroplasty lead to increased physical activity as measured by accelerometer?
- Does vertebroplasty lead to increased mobility as measured by GPS (global positioning system)?
- Do physical activity and mobility correlate with pain, disability and quality of life?
Researchers will compare vertebroplasty to sham (simulated surgery without active intervention) to understand if vertebroplasty improves physical activity and mobility.
Participants will
- Undergo vertebroplasty or sham procedure
- Wear an accelerometer and a GPS-reciever in a belt for 1 week before to 4 weeks after the surgery
- Answer questionnaires regarding pain, disability and quality of life at regular intervals.
The knowledge gained from this can help determine who would benefit from vertebroplasty.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite attempts at prevention, osteoporotic vertebral fracture occurs with increasing frequency as lifespans increase.
Patients with this disease can experience severe pain and disability, and when conservative treatment is inadequate, vertebroplasty is an option.
In this surgical procedure, polymethyl metacrylate, or "bone cement" is injected into the fractured vertebral body. However, the procedure is currently controversial for the treatment of osteoporotic vertebral fractures because there is not yet consensus on the efficacy.
By investigating the effect of vertebroplasty on mobility and physical activity, this study aims to contribute to resolution of the controversy.
The study is a prospective, double-blind, randomized, sham-controlled clinical trial, where participants will be randomized to either vertebroplasty or a sham operation.
The study is embedded in the ongoing trial "Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy (VOPE2)" with ClinicalTrials.gov ID NCT06141187.
A subset of the participants in VOPE2 will, in addition to previously planned activities, be equipped with wearable accelerometers and a global positioning system (GPS).
The trial is designed in accordance with the SPIRIT guidelines.
Potential participants will be identified by referral to the Center for Spine Surgery and Research from general practitioners, chiropractor, physiotherapist, or from hospital inpatient and emergency departments in the region of Southern Denmark.
Participants will then be examined in an outpatient clinic by a spine surgeon, and have MRI scans and X-ray images analyzed by experienced neuro-radiologists.
If eligible, they will be offered to participate following informed consent. An accelerometer and GPS-reciever attached to an elastic waist band are initiated following inclusion.
Subjects will initially be stratified into two groups based on the number of OVCFs into 1-2 levels or 3-4 levels.
Within each of these two groups, randomization sheets in varying blocks of 8 with an equal number of PVP and sham patients in each block will be generated using software (www.randomizer.org) and will be placed in numbered, opaque, sealed envelopes.
Treatment group assignment is 1:1 and will be performed by a scrub nurse in the surgical theatre after the patient is draped but prior to skin incision.
Throughout the trial, only the surgeon and the OR-nurse will have knowledge of the treatment assignment.
The patient and all assessors remain blinded to the treatment group throughout the study. Spine surgeons who are experienced in PVP will perform the surgical procedures.
Anaesthesiologists and spine surgeons are present at the facility in case of complications, following recommendations by the National Health Authority and have the capacity/capability to decompress the spinal canal in case of cement leakage
Based on qualitative studies and clinical experience, patients with painful osteoporotic vertebral fractures restrict their movement because of pain.
This in turn leads to reduced physical activity and diminished ability to move oneself around and away from home, defined here as mobility.
If vertebroplasty is effective, it is expected to lead to increased physical activity and mobility compared to sham, and the outcomes derived from accelerometers and GPS-recievers can supplement patient reports due to their continuous and objective nature.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Søren W Sørensen, MD
- Phone Number: 0045 76362000
- Email: soren.wittorff.sorensen@rsyd.dk
Study Locations
-
-
-
Kolding, Denmark, 6000
- Recruiting
- Spine Centre of Southern Denmark
-
Contact:
- Søren W Sørensen, MD
- Phone Number: 0045 76 36 20 00
- Email: soren.wittorff.sorensen@rsyd.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 50+ and diagnosed with symptomatic osteoporotic spinal compression fractures between T6 and L5 (incl).
- Focal tenderness on the level of the vertebral fracture.
- Fractures verified with oedema of the relevant vertebra on the MRI STIR sequence.
- Osteoporotic Fractures type 1-4.
- Fracture involves no more than 4 vertebral body levels.
- Vertebroplasty can be done in one session.
- Back pain score measured on a Visual Analog Scale (VAS, 0 to 100) ≥ 60.
- Able to understand and read Danish.
- Written informed consent.
- Relevant pain started ≤ 3 months prior to enrollment.
Exclusion Criteria:
- Contra-indications for spine surgery.
- Platelets < 30 mia/l.
- Osteoporotic Fractures type 5 and Pincer-type.
- Complete collapse of the vertebral body precluding insertion of needle.
- Presence of neurologic deficit.
- Contraindications for MRI scanning.
- Psychological or psychiatric disorder that is expected to interfere with compliance.
- Active malignancy.
- Mini Mental State Examination (MMSE) test score below 24.
- History of chronic back pain requiring ongoing opiate use.
- Systemic or local infection of the spine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Vertebroplasty
Polymethyl-methacrylate (PMMA) cement is prepared and injected slowly into the vertebral body under constant bi-plane fluoroscopy Interventions: Procedure: Vertebroplasty |
Polymethyl-methacrylate (PMMA) cement is injected slowly into the vertebral body under constant bi-plane fluoroscopy
Other Names:
|
|
Sham Comparator: Sham vertebroplasty
A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body. Interventions: Procedure: Sham Vertebroplasty |
A short needle is passed through the skin, but not as far as the periosteum.
PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in physical activity before and after intervention
Time Frame: One week preoperatively to the end of the fourth postoperative week.
|
Physical activity is measured by accelerometer and presented as mean ENMO (euclidian norm minus one) and mean TAC/d (total activity count per day). An unweighted average of valid days within the preoperative week is compared with the unweighted average of valid days within the four postoperative weeks by relative change in percent. |
One week preoperatively to the end of the fourth postoperative week.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily and weekly physical activity
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Physical activity is measured by accelerometer and presented as difference in mean ENMO (euclidian norm minus one) and mean TAC/d (total activity count per day).
Daily means are based on valid wear-time.
Weekly means are calculated as unweighted averages of all valid days within the week.
|
One week preoperatively to 4 weeks postoperatively
|
|
Change in daily and weekly physical activity
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Physical activity is measured by accelerometer and presented as difference in mean ENMO (euclidian norm minus one) and mean TAC/d (total activity count per day). Daily means are based on valid wear-time. Weekly means are calculated as unweighted averages of all valid days within the week. This outcome supplements the primary outcome to cover changes within the full study period. Changes are reported as relative percentages. |
One week preoperatively to 4 weeks postoperatively
|
|
Physical activity levels
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Based on cut-points applied to the ENMO or count measurements, the valid wear-time is divided into intensity classes "sedentary", "light activity" or "moderate to vigorous activity".
Time spent in each class is presented as percentage of valid wear-time.
|
One week preoperatively to 4 weeks postoperatively
|
|
Change in physical activity levels
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Based on cut-points applied to the ENMO or count measurements, the valid wear-time is divided into intensity classes "sedentary", "light activity" or "moderate to vigorous activity".
Time spent in each class is presented as percentage of valid wear-time and changes as absolute percentage points.
|
One week preoperatively to 4 weeks postoperatively
|
|
Total daily distance and change in total daily distance
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Total daily distance traveled in meters based on GPS positions.
Changes are relative in percentages.
|
One week preoperatively to 4 weeks postoperatively
|
|
Time spent stationary and change in time spent stationary
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Percentage of time spent stationary based on GPS positions relative to the days' recording.
Change is absolute percentage points.
|
One week preoperatively to 4 weeks postoperatively
|
|
Time spent away from home and change in time spent away from home
Time Frame: One week preoperatively to 4 weeks postoperatively
|
Percentage of time per day where the GPS records a position away from home relative to the days' recordings.
Change is in absolute percentage points.
|
One week preoperatively to 4 weeks postoperatively
|
|
Patient-reported pain intensity.
Time Frame: VAS will be recorded once preoperatively and again 1, 2, 3, 4 and 5 days + 2 and 4 weeks postoperatively.
|
Pain intensity over the previous 24 hours using the 100-point visual analog scale, where 0 is no pain and 100 is the worst imaginable pain.
|
VAS will be recorded once preoperatively and again 1, 2, 3, 4 and 5 days + 2 and 4 weeks postoperatively.
|
|
Patient-reported disability
Time Frame: Preoperatively and at 4 weeks postoperatively
|
The patients rate their disability using the Oswestry Disability Index (ODI) questionnaire.
|
Preoperatively and at 4 weeks postoperatively
|
|
Patient-reported health-related quality of life.
Time Frame: Preoperatively and at 4 weeks postoperatively
|
Health-related quality of life.
on the EuroQol 5-dimension 5-level (EQ-5D-5L)
|
Preoperatively and at 4 weeks postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mikkel Ø Andersen, Prof, MD, Spine Centre of Southern Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23/40938
- 112199 (Registry Identifier: Den Videnskabsetiske Komité for Region Syddanmark)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporotic Vertebral Compression Fractures
-
Xin FanNot yet recruitingOsteoporotic Vertebral Compression FracturesChina
-
Optimus Clinical ResearchCareFusionCompletedVertebral Compression Fractures | Osteoporotic Vertebral Compression Fractures | Acute Vertebral FracturesAustralia
-
Icahn School of Medicine at Mount SinaiTerminatedVertebral Compression Fractures | Osteoporotic Vertebral Compression FracturesUnited States
-
Beijing Friendship HospitalRecruitingOsteoporotic Vertebral Compression Fractures | VertebroplastyChina
-
Stryker InstrumentsTalosixCompleted
-
University of VirginiaCook Group Incorporated; ArthroCare Corporation; Cardinal HealthCompletedOsteoporotic Vertebral Compression FracturesUnited States
-
Wiltrom Co., Ltd.AvaniaActive, not recruitingOsteoporotic Vertebral Compression FracturesGermany
-
Eva Koetsier MD PhDProf. Dr. Med. Alessandro Cianfoni, MD PhD, Neurocenter of Southern Switzerland...Not yet recruitingUnstable Osteoporotic Vertebral Compression FracturesSwitzerland
-
Shenzhen People's HospitalCompletedOsteoporotic Vertebral Compression FractureChina
-
University Hospital, Strasbourg, FranceUnknownVertebral Compression Fractures in Osteoporotic PatientsFrance
Clinical Trials on Vertebroplasty
-
Centre Leon BerardTerminated
-
University of BernSonnenhof Hospital, BernTerminatedOsteoporosis | Vertebral FractureSwitzerland
-
Centre Leon BerardTerminatedSolid Tumors | Spine MetastasisFrance
-
Li MinRecruiting
-
Spine Centre of Southern DenmarkRecruitingMultiple Myeloma | Vertebral FractureDenmark
-
Optimus Clinical ResearchCareFusionCompletedVertebral Compression Fractures | Osteoporotic Vertebral Compression Fractures | Acute Vertebral FracturesAustralia
-
McGill University Health Centre/Research Institute...UnknownPain | Breast Cancer | Prostate Cancer | Vertebral MetastasisCanada
-
Prof Nicolas TheumannJohnson & Johnson; Dr Danoob DaliliRecruitingPathological Fracture | Vertebral Compression Fractures | Facet Joint ArthropathySwitzerland
-
Spine Centre of Southern DenmarkRecruitingVertebral Fracture | Osteoporotic FracturesDenmark
-
University Hospital of PatrasSt. Andrew's General Hospital, Patras, GreeceCompletedThoracic Fracture | Lumbar Fracture